MedTrace Logo

Rasburicase Treatment in Chronic Gouty Arthritis

NCT05312268 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-05-09

No results posted yet for this study

Summary

The study will establish efficacy and safety of rasburicase in chronic gouty arthritis

Conditions

  • Chronic Gout

Interventions

DRUG

Rasburicase

Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.

Sponsors & Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Qianhua Li, M.D.&Ph.D · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2024-10-15
Completion
2025-04-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312268 on ClinicalTrials.gov